GlycoMimetics lands $38M round to fund new trials

Genzyme Ventures has joined an A-list group of venture companies who are backing Gaithersburg, MD-based GlycoMimetics with a $38 million financing round. New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures also joined the round.

The new investment will be used to fund a Phase II trial of GlycoMimetics' lead drug candidate--GMI-1070--in vaso-occlusive crisis of sickle cell disease. The compound is a glycomimetic inhibitor of E-, P- and L-selectins, and inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue. The company also intends to use proceeds to fund a Phase II study of GMI-1070 in a second clinical indication. 

"GlycoMimetics has made excellent progress in the discovery and development of new glycobiology-based medicines," said Alan Walts, managing director of Genzyme Ventures. "GlycoMimetics is a lean, focused company, and we`re very encouraged by their progress," said Jim Barrett, general partner of New Enterprise Associates, which has led each of the company`s investment rounds.

- check out the GlycoMimetics release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.